Bruder Healthcare, a Hilco Vision Company, entered into an exclusive distribution agreement with Santen S.A. to market Eyeleve MGD in the United States. To be marketed in early 2025 as Eyeleve MGD, the eyedrop formulation was previously marketed in the United States as Retaine MGD, Bruder said in a press release. The preservative-free ophthalmic emulsion provides moisturization, lubrication and protection for moderate to severe evaporative dry eye. 

According to Bruder, the formulation uses a preservative-free oil-in-water cationic emulsion technology. This technology delivers ingredients through electrostatic attraction between positively charged droplets and the negatively charged ocular surface. 

The hypotonicity of the emulsion in Eyeleve MGD adds moisture by lowering the salt concentration of tears, while the lipid component lubricates and protects the surface of the eye. This combination of ingredients, Bruder says, ensures that patients experience relief from dry eye symptoms, improving their overall eye health and comfort.